Home Cart Sign in  
Chemical Structure| 978-62-1 Chemical Structure| 978-62-1

Structure of IMD-0354
CAS No.: 978-62-1

Chemical Structure| 978-62-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

IMD-0354 (IKK2 Inhibitor V) selectively inhibits IKKβ, reducing NF-κB activity. IMD0354 also inhibits TNF-α induced NF-κB transcription activity with an IC50 of 1.2 μM.

Synonyms: IKK2 Inhibitor V

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of IMD-0354

CAS No. :978-62-1
Formula : C15H8ClF6NO2
M.W : 383.67
SMILES Code : O=C(NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1)C2=CC(Cl)=CC=C2O
Synonyms :
IKK2 Inhibitor V
MDL No. :MFCD00218820
InChI Key :CHILCFMQWMQVAL-UHFFFAOYSA-N
Pubchem ID :5081913

Safety of IMD-0354

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of IMD-0354

pyroptosis
TLR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Bone marrow monocytes (BμMs) 0.25, 0.5, 1 μM 6 days IMD-0354 significantly inhibited RANKL-induced osteoclast differentiation, reducing the number, area, and size of osteoclasts, with more pronounced effects in the late differentiation stage. PMC6737093
RAW264.7 cells 1 μM 0, 1, 3, 5 days IMD-0354 inhibited osteoclast-specific gene expression, such as NFATc1, TRAP, c-Fos, and CTSK. PMC6737093
Calvarial osteoblasts 0.25, 0.5, 1 μM 7 days IMD-0354 did not significantly affect osteoblast differentiation and mineralization. PMC6737093

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Hypertensive retinopathy model Intraperitoneal injection 3.95 mg/mL Every other day for 10 days IMD-0354 remarkably blocked Ang II-induced increases in retinal vascular permeability, oxidative stress, and inflammation. PMC5952914
Mice Ovariectomy-induced osteoporosis model Intraperitoneal injection 150 mg/kg Once daily for 7 days IMD-0354 significantly inhibited ovariectomy-induced bone loss, reducing the number and activity of osteoclasts, but did not affect bone formation. PMC6737093
Mice KKay mouse model Intracerebroventricular injection 0.23 mg/kg, 0.92 mg/kg Twice a week for 4 weeks IMD-0354 improved the abnormalities in glucose tolerance and insulin sensitivity induced by PM2.5 exposure in mice and restored energy metabolism parameters (such as O2 consumption, CO2 production, and heat generation). PMC4226918

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.61mL

0.52mL

0.26mL

13.03mL

2.61mL

1.30mL

26.06mL

5.21mL

2.61mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories